Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 12, 2012, Pages 1481-1486

  Michel Monigadon, Delphine ^a   Steffens, Sabine ^a   Molica, Filippo ^a   Mach, François ^a   Montecucco, Fabrizio ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

angiogenesis; atherosclerosis; endocannabinoid system; matrix metalloproteinases

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; GELATINASE A; GELATINASE B; VANILLOID RECEPTOR 1;

ANGIOGENESIS; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL MIGRATION; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SMOOTH MUSCLE FIBER;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; ENDOCANNABINOIDS; GELATINASES; HUMANS; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CANNABINOID;

EID: 84871485098     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.145     Document Type: Article

References (61)

1. Welgus HG, Campbell EJ, Cury JD et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J. Clin. Invest. 86(5), 1496-1502 (1990).
2. Lenglet S, Thomas A, Chaurand P, Galan K, Mach F, Montecucco F. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. Thromb. Haemost. 107(3), 409-416 (2012).
3. Vuilleumier N, Bas S, Pagano S et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 62(9), 2640-2650 (2010).
4. Muroski ME, Roycik MD, Newcomer RG et al. Matrix metalloproteinase-9/ gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr. Pharm. Biotechnol. 9(1), 34-46 (2008).
5. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 1825(1), 29-36 (2012).
6. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul. Pharmacol. 56(5-6), 232-244 (2012).
7. Ketelhuth DF, Bäck M. The role of matrix metalloproteinases in atherothrombosis. Curr. Atheroscler. Rep. 13(2), 162-169 (2011).
8. Montecucco F, Vuilleumier N, Pagano S et al. Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur. Heart J. 32(4), 412-421 (2011).
9. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: A general view and latest additions. Br. J. Pharmacol. 141(5), 765-774 (2004).
10. Montecucco F, Di Marzo V, da Silva RF et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur. Heart J. 33(7), 846-856 (2012).
11. Montecucco F, Matias I, Lenglet S et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 205(2), 433-441 (2009).
12. Sugamura K, Sugiyama S, Nozaki T et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119(1), 28-36 (2009).
13. Bonz A, Laser M, Küllmer S et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol. 41(4), 657-664 (2003).
14. Bátkai S, Pacher P, Osei-Hyiaman D et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110(14), 1996-2002 (2004).
15. Mukhopadhyay P, Bátkai S, Rajesh M et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol. 50(6), 528-536 (2007).
16. Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115(5), 1298-1305 (2005).
17. Engeli S, Böhnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54(10), 2838-2843 (2005).
18. Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am. J. Physiol. Gastrointest. Liver Physiol. 294(1), G9-G12 (2008).
19. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin. Immunopathol. 31(1), 63-77 (2009).
20. Randall MD. Endocannabinoids and the haematological system. Br. J. Pharmacol. 152(5), 671-675 (2007).
21. Van Sickle MD, Duncan M, Kingsley PJ et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310(5746), 329-332 (2005).
22. Pacher P, Gao B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: Implications for inflammatory liver diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 294(4), G850-G854 (2008).
23. Rajesh M, Mukhopadhyay P, Bátkai S et al. CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 293(4), H2210-H2218 (2007).
24. Rajesh M, Mukhopadhyay P, Haskó G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-α-induced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol. 153(2), 347-357 (2008).
25. Quercioli A, Pataky Z, Vincenti G et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur. Heart J. 32(11), 1369-1378 (2011).
26. Járai Z, Wagner JA, Varga K et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl Acad. Sci. USA 96(24), 14136-14141 (1999).
27. O'Sullivan SE, Kendall DA, Randall MD. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br. J. Pharmacol. 142(3), 435-442 (2004).
28. Herradón E, Martín MI, López-Miranda V. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br. J. Pharmacol. 152(5), 699-708 (2007).
29. Mukhopadhyay S, Chapnick BM, Howlett AC. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am. J. Physiol. Heart Circ. Physiol. 282(6), H2046-H2054 (2002).
30. Wagner JA, Varga K, Járai Z, Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33(1 Pt 2), 429-434 (1999).
31. McCollum L, Howlett AC, Mukhopadhyay S. Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothe-lial cells. J. Pharmacol. Exp. Ther. 321(3), 930-937 (2007).
32. Montecucco F, Di Marzo V. At the heart of the matter: The endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol. Sci. 33(6), 331-340 (2012).
33. Zygmunt PM, Petersson J, Andersson DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400(6743), 452-457 (1999).
34. Ralevic V, Kendall DA, Randall MD, Zygmunt PM, Movahed P, Högestätt ED. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br. J. Pharmacol. 130(7), 1483-1488 (2000).
35. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ. Res. 87(8), 670-676 (2000).
36. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75(2), 346-359 (2008).
37. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9(6), 653-660 (2003).
38. Risau W. Mechanisms of angiogenesis. Nature 386(6626), 671-674 (1997).
39. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 22(7), 251-256 (1997).
40. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21(7), 1104-1117 (2001).
41. De Filippis D, Russo A, De Stefano D et al. Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-κB activation. J. Mol. Med. (Berl.) 85(6), 635-645 (2007).
42. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. FASEB J. 17(12), 1771-1773 (2003).
43. Casanova ML, Blázquez C, Martínez-Palacio J et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111(1), 43-50 (2003).
44. Blazquez C, Casanova ML, Planas A et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17(3), 529-531 (2003).
45. Pisanti S, Picardi P, Prota L et al. Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. Blood 117(20), 5541-5550 (2011).
46. Blázquez C, Salazar M, Carracedo A et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res. 68(6), 1945-1952 (2008).
47. Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl Cancer Inst. 100(1), 59-69 (2008).
48. Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem. Pharmacol. 79(7), 955-966 (2010).
49. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 85(1), 1-31 (2005).
50. Johnson C, Galis ZS. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler. Thromb. Vasc. Biol. 24(1), 54-60 (2004).
51. Johnson JL, Dwivedi A, Somerville M, George SJ, Newby AC. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler. Thromb. Vasc. Biol. 31(9), e35-e44 (2011).
52. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94(6), 2493-2503 (1994).
53. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc. Res. 59(4), 812-823 (2003).
54. Blankenberg S, Rupprecht HJ, Poirier O et al.; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107(12), 1579-1585 (2003).
55. Netherland CD, Pickle TG, Bales A, Thewke DP. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213(1), 102-108 (2010).
56. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group. SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive Type 2 diabetes. Diabetes Care 31(11), 2169-2176 (2008).
57. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 295(7), 761-775 (2006).
58. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365(9468), 1389-1397 (2005).
59. Topol EJ, Bousser MG, Fox KA et al.; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): A randomised, multicentre, placebo-controlled trial. Lancet 376(9740), 517-523 (2010).
60. Hoyer FF, Steinmetz M, Zimmer S et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J. Mol. Cell. Cardiol. 51(6), 1007-1014 (2011).
61. Willecke F, Zeschky K, Ortiz Rodriguez A et al. Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. PLoS ONE 6(4), e19405 (2011).